E-Mail
(Boston) Newly published National Institute of Neurological Disorders and Stroke (NINDS) Consensus Diagnostic Criteria for Traumatic Encephalopathy Syndrome (TES) are the first expert consensus criteria developed for the clinical disorder associated with Chronic Traumatic Encephalopathy (CTE) brain pathology. CTE is a degenerative brain disease associated with a history of repetitive head impacts, including those sustained in contact and collision sports such as American football and boxing. At this time, CTE can only be diagnosed after death through a neuropathological examination of brain tissue. There has been no accepted approach or agreed upon criteria for the diagnosis of CTE and its clinical manifestations during life until now.
E-Mail
IMAGE: Claudia Angeli, Ph.D., left, with UofL research participants Kelly Thomas and Jeff Marquis and trainer Kristin Benton view more
Credit: University of Louisville
LOUISVILLE, Ky. - Researchers at the University of Louisville made news worldwide in 2018 when two people diagnosed with complete spinal cord injuries recovered the ability to walk thanks to experimental use of a therapy known as epidural stimulation. The news gave hope to people living with complete spinal cord injuries, a diagnosis that historically meant they were unlikely to regain function below their level of injury.
Despite these significant results, use of epidural stimulation outside a research lab setting to restore function for people with spinal cord injury thus far has been hampered by several limitations, including the use of a technology that was designed for patients with chronic, intractable pain - not those with spinal cord injury.
Criteria Proposed to Diagnose Clinical Syndrome Tied to CTE medpagetoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medpagetoday.com Daily Mail and Mail on Sunday newspapers.
Researchers have found that in some people with severe COVID-19, the immune system goes rogue and attacks one of its own key defenses instead of fighting the coronavirus.
Stroke-Targeting Nanoparticles Deliver Neuroprotectant to Mouse Brain
Written by AZoNanoMar 12 2021
According to a new study, the delivery of NA1, a neuroprotectant, to the brain in nanoparticles decreases stroke severity and enhances survival in a mouse model of stroke.
Image Credit: Alexandros A Lavdas/shutterstock.com
This is a preliminary study to be presented at the American Stroke Association’s International Stroke Conference 2021. The virtual meeting will be held from March 17
th to 19
th, 2021, and is a world premiere meeting for clinicians and researchers committed to the science of stroke and brain health.
In a previous human trial (the ESCAPE-NA1 trial), NA1, a small peptide that has been particularly developed to save brain cells from death following stroke, exhibited combined outcomes when NA1 was given to patients who were undergoing clot removal for severe stroke.